This article is more than 5 years old. Information may no longer be current.

VIDEO: Pembrolizumab represents ‘important option’ for metastatic urothelial cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Improvements in response duration and side effect profile seen in the KEYNOTE-045 trial of pembrolizumab establish this therapy “as a standard of care” for patients with previously treated, metastatic urothelial cancer, according to Matthew Galsky, MD, professor of medicine (hematology and medical oncology) and urology at the Icahn School of Medicine at Mount Sinai Hospital in New York.

“This study reinforces some of the single arm, phase 2 experience with immune checkpoint blockade,” Galsky told HemOnc Today. “These treatments represent an important option for patients who have received platinum-based chemotherapy.”